2nd Quarter - Report

MEHLMAN CONSULTING, INC. for VIZIENT INC

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues. 340B Drug Pricing Program. COVID-19 supply chain and pharmaceutical, PPE, and other health care supply chain issues.

LobbyistCovered position, as disclosed
LAUREN ARONSON —
DEAN ROSEN —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE

Medicare/Medicaid MMM

Healthcare transparency, costs and access to affordable medication and other healthcare items and services.

LobbyistCovered position, as disclosed
LAUREN ARONSON —
DEAN ROSEN —

Contacted: White House Office; Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Pharmacy PHA

Issues related to Unapproved Drug Initiative.

LobbyistCovered position, as disclosed
LAUREN ARONSON —
DEAN ROSEN —

Contacted: SENATE; White House Office; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.